
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is a preclinical biotechnology company that uses AI technology to develop precision antibodies. The company has a strong body of preclinical results and is on pace to file an IND/CTA by year-end 2026 for IBIO-610, its second clinical asset. It also faces significant competition in the industry and may need to raise additional funds for its research and development programs.
Bears say
iBio is a development stage company that relies heavily on intellectual property to protect its potential products, however, its patents and patent applications may not provide sufficient protection from competitors. The company also faces significant competition from larger, more established biotechnology and pharmaceutical companies, and will likely need to raise significant funds in the future to continue its operations. With no current revenue generating products, there are significant financial risks associated with investing in iBio.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares